GLX351322, a selective inhibitor of NOX4, has been suggested to be effective in T2D [276], while Plumbagin, another Nox4 specific inhibitor, has been reported to counteract oxidative stress-induced endothelial dysfunction and preadipocyte apoptosis under hyperinsulinemic conditions [277,278]. Here, NOX4 is linked to type 2 diabetes mellitus.